Combined serum miR-29c and miR-149 expression analysis as diagnostic genetic markers for colorectal cancer

Colorectal Cancer
18/07/2020

Biotechnol Appl Biochem. 2020 Jul 17. doi: 10.1002/bab.1986. Online ahead of print.

ABSTRACT

Circulating miRNAs gathered much interest in cancer research as noninvasive biomarkers. The aim of this study was to analyze the expression of miR-29c and miR-149 among colorectal cancer (CRC) patients and to explore their diagnostic and prognostic potentials in relation to the clinical and pathological features. The expression levels of miR-29c and miR-149 were evaluated in the sera of 80 CRC, 80 colorectal adenoma (CRA) patients and 80 healthy controls using quantitative real time polymerase


chain reaction. CEA serum levels were assayed using ELISA. miR-29c and miR-149 were significantly down-regulated among CRC patients compared to CRA and controls (miR-29c, 0.54±0.19 vs. 0.86±0.12, 0.99±0.07, P<0.001 respectively; miR-149, 0.46±0.19 vs. 0.74±0.012, 1.0±0.22, P<0.001 respectively) miR-29c and miR-149 significantly associated with advanced stages of CRC, tumor size and lymphatic metastasis. By using receiver operating characteristic curve analysis, combined miR-29c and miR-149 revealed the highest diagnostic potential for CRA [area under the curve (AUC) = 0.967] from healthy controls as well as the diagnosis of CRC (AUC = 0.98) from CRA. Moreover, combined miRNAs revealed high diagnostic potential for the earlier stages of CRC compared to advanced stages (AUC = 0.96) In conclusion, combined serum miR-29c and miR-149 expression analysis established novel non-invasive biomarker for early CRC diagnosis. This article is protected by copyright. All rights reserved.